Company / Net Income
X4 Pharmaceuticals, Inc Net Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$101.2M
FY2025
5-year range
-$101.2M / -$33.3M
FY2021-FY2025
Trend
-7.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has declined for 5 consecutive years, from -$23M in FY2018 to -$101M in FY2025.
Based on SEC 10-K filings.
-$101M in FY2025.
Declined from -$62M to -$101M over the past 3 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- X4 Pharmaceuticals, Inc's net income has declined for 5 consecutive years.
- In FY2025, net income decreased 7.8% year-over-year.
- Peak net income was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$101.2M | -7.8% |
| FY2024 | -$93.9M | -51.1% |
| FY2022 | -$62.1M | -17.7% |
| FY2021 | -$52.8M | -58.7% |
| FY2020 | -$33.3M | -44.9% |
| FY2018 | -$23.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026